Sapience Therapeutics, Inc. — Form D
Sapience Therapeutics, Inc. of HARRISON, NY, a company, filed a Form D exempt-offering notice with the SEC on 2020-07-13. The offering totals $30.0M, of which $8.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2020-07-13
- Form: D
- Accession: 0001009448-20-000004
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $30.0M
- Amount sold: $8.0M
- Remaining: $22.0M
- Minimum investment: $50K
- Investors: 83
- Date of first sale: 2020-06-29
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-370845
Issuer
- Name: Sapience Therapeutics, Inc.
- CIK: 0001661731
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 500 MAMARONECK AVENUE, HARRISON, NY, 10528
- Phone: (914) 607-6931
Officers, directors & promoters (11)
| Name | Role | Location |
|---|
| Barry Kappel | Director | Harrison, NY |
| Howard Pien | Director | Harrison, NY |
| Robert Ruffolo | Director | Boston, MA |
| Christian Schade | Director | Harrison, NY |
| David Scheinberg | Director | Harrison, NY |
| Barry Kappel | Executive Officer | Harrison, NY |
| Isaac Blech | Director | Jupiter, FL |
| Robert Ruffolo, Ph.D. | Director | Scarsdale, NY |
| Barry Kappel, Ph.D. | Director | Scarsdale, NY |
| Barry Kappel, Ph.D. | Executive Officer | Scarsdale, NY |
| David Scheinberg, Ph.D. | Director | Scarsdale, NY |
Other filings by this issuer (2)
More